Learn More
OBJECTIVE The purpose of this study was to compare costs and treatment patterns between men with concomitant benign prostatic hyperplasia (BPH) and CVD to men with CVD (but not BPH). STUDY DESIGN A(More)
635 Background: In a randomized phase III clinical trial, the overall tumor response rate in MBC patients was 33% for ABX (260 mg/m2 infused IV over 30 minutes every 3 weeks for a median of 6 cycles)(More)
  • 1